StockData

Kazia Therapeutics vs NeOnc Technologies

KZIA and NTHI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KZIA and NTHI compare

Kazia Therapeutics scores higher on the StockData Score (1 against 0 for NeOnc Technologies), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKZIANTHI
Size and price
Market cap–$112M
Share price$5.31$4.33
Change, 1 year−15.3%−52.3%
Change, 5 years−98.9%–
Beta (5Y)4.082.81
Employees145
StockData Score
Total score1 (better)0
Valuation score00
Growth score00
Performance score00
Health score1 (better)0
Dividend score00
Growth
Revenue growth (TTM)−98.2%–
Profitability
Net margin−49291%–
Financial health
Interest coverage–−15.7×
Current ratio2.87 (better)0.38
Altman Z-score–−34.30
Piotroski F-score22
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions0.45%12.2%
Held by insiders0.29%60.1%
Insider net buying, 12 months–$2.0M
Superinvestors holding1–
Short interest, % of float–8.9%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.